Nutrition Blood Outcomes Following Tocotrienol N2B (NIIB)

• ClinicalTrials.gov Identifier: NCT01858311
• Recruitment Status: Completed
• First Posted: May 21, 2013
• Last Update Posted: September 20, 2021
• Sponsor: Ohio State University
• Collaborator: Malaysia Palm Oil Board
• Information provided by (Responsible Party): Andrew Slivka, Ohio State University

Study Description

Brief Summary:

A natural form of vitamin E called tocotrienol (TCT) has blood thinning and cholesterol lowering properties, both of which may benefit stroke survivors. This study is being conducted to determine the blood thinning and cholesterol lowering properties of TCT in stroke or TIA (transient ischemic attack, which is also referred to as a "mini-stroke") survivors that are receiving the standard treatment for prevention of recurrent stroke.

Study Hypothesis: Oral TCT decreases the incidence of aspirin and clopidogrel nonresponders, increases the extent of inhibition of platelet aggregation, and decreases LDL without significant side effects in stroke patients.

Condition or disease	Intervention/treatment
Stroke	Dietary Supplement: Tocotrienol Capsules; Other: Placebo Vehicle

Detailed Description:

In this Phase IIB trial the goal is to determine the effects of orally supplemented TCT on platelet function and cholesterol as well as the safety in patients with TIA (transient ischemic attack) or stroke in addition to the standard treatment for stroke prevention. Recurrent cardiovascular events including stroke, TIA, heart attack, venous thrombosis, pulmonary embolism, systemic embolism will also be recorded. In patients with recurrent stroke, severity of the stroke and stroke size measured from MR (magnetic resonance) or CT (computed tomography) imaging will also be collected. We expect that TCT will inhibit blood clotting and lower cholesterol more than current standard treatment without significantly increasing bleeding risks or other side effects. Future work is planned in a larger TIA/stroke population to examine whether TCT adds to standard medical care in terms of decreasing incidence of stroke and improving outcomes following stroke.

Study Design

• Study Type: Observational
• Actual Enrollment: 300 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Human Blood Outcomes Following Tocotrienol Supplementation - Nutrition Phase IIB NUTRITION PHASE IIB
• Study Start Date: March 2013
• Actual Primary Completion Date: September 2018
• Actual Study Completion Date: December 2018

Groups and Cohorts

Group/Cohort	Intervention/treatment
Placebo vehicle; (2) placebo capsules following AM meal and (2) placebo capsules following PM meal.	Other: Placebo Vehicle; Placebo capsules per day (2 in the morning and 2 in the evening)
Tocotrienol capsules (400 mg); (2) 100mg TCT capsules following AM meal and (2) 100mg TCT capsules following PM meal.	Dietary Supplement: Tocotrienol Capsules; Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
Tocotrienol Capsules (800 mg); (2) 200mg TCT capsules following AM meal and (2) 200mg TCT capsules following PM meal.	Dietary Supplement: Tocotrienol Capsules; Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)

Outcome Measures

Primary Outcome Measures :

1. platelet aggregation activity [ Time Frame: up to 1 year ]
   Platelet aggregation activity will be measured using standard clinical laboratory procedures

Secondary Outcome Measures :

1. Incidence of recurrent stroke [ Time Frame: up to 1 year ]
   Incidence of recurrent stroke after previous diagnosed stroke or TIA.

Biospecimen Retention:   Samples With DNA

Blood Draw

Eligibility Criteria

• Ages Eligible for Study: Child, Adult, Older Adult
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

Stroke survivors within 6 months of clinical presentation for ischemic stroke or TIA event

Criteria

Inclusion Criteria:

• Patients with either atherothrombotic, cardioembolic, cryptogenic stroke or TIA (transient ischemic attack) for whom anticoagulation is not indicated
• Enrollment in trial must occur within 6 months of clinical presentation for first stroke or TIA event
• No history of long-term vitamin E supplement (defined as daily oral tocopherol or tocotrienol supplementation at least 6mos; within the past 5 years)
• No current vitamin E supplementation in multi-vitamin

Exclusion Criteria:

• Disabling stroke ( Modified Rankin Scale > 3)
• Prior intracranial hemorrhage (excluding traumatic)
• High risk of bleeding (recurrent gastrointestinal, genitourinary bleeding, active peptic ulcer disease)
• Anticipated requirement for long term use of anticoagulation
• Contraindications to antiplatelet agents (bleeding disorder, thrombocytopenia, prolonged INR)
• Irreversible medical condition likely to affect short-term survival or ability to participate in study such as cancer or other chronic disease with predicted survival of less than a year or severe psychiatric or neurologic disease that might complicate evaluation of study outcomes like dementia or schizophrenia
• Pregnancy or women of child bearing age who are not following an effective method of contraception
• Breast feeding
• Unable or unwilling to provide informed
• Unlikely to be compliant with therapy or unwilling to return for follow up frequent clinic visits
• Concurrent participation in another study with an investigational drug or devise
• Other likely specific cause of stroke such as dissection, infectious or noninfectious vasculitis, prothrombotic state

Contacts and Locations

Locations

United States, Ohio

The Ohio State University

Columbus, Ohio, United States, 43210

Mount Carmel Health System

Columbus, Ohio, United States, 43213

Sponsors and Collaborators

Ohio State University

Malaysia Palm Oil Board

More Information

• Responsible Party: Andrew Slivka, MD, Professor of Neurology, Ohio State University
• ClinicalTrials.gov Identifier: NCT01858311
• Other Study ID Numbers: 2012H0113
• First Posted: May 21, 2013
• Last Update Posted: September 20, 2021
• Last Verified: September 2021

Keywords provided by Andrew Slivka, Ohio State University:

Stroke survivors; TIA survivors; Vitamin E; Carotech; Tocotrienol

Additional relevant MeSH terms:

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Tocotrienols; Vitamin E; Tocopherols; Antioxidants; Molecular Mechanisms of Pharmacological Action; Protective Agents; Physiological Effects of Drugs; Vitamins; Micronutrients